Rocket Pharma (RCKT) Stock Forecast & Price Target

Rocket Pharmaceuticals is supported by a clearer regulatory path for RP-A501 in Danon disease, as the FDA kept the pivotal Phase 2 design intact, including the 12-patient cohort and the original 12-month co-primary endpoints tied to myocardial LAMP2 expression and a 10% LVMI reduction. The recalibrated dose of 3.8 x 10¹³ GC/kg, plus the removal of prophylactic C3 complement inhibition, has already shown good tolerability in three patients with no TMA, no capillary leak syndrome, and no other significant safety concerns, reducing a major clinical overhang. Its outlook is further strengthened by a $283.7M cash balance at the end of 2Q26, a runway into 2Q28, and the possibility that RP-A501 could become a major value driver in a disease with high unmet need and limited therapy options.

Rocket Pharmaceuticals is viewed negatively because its core value drivers remain largely unproven, with most programs still in Phase I/II and the Danon disease pivotal phase II study already hit by a clinical hold after serious adverse events in May 2025, including one fatality. The company is an early commercial-stage biotech with one approved product that is not yet generating revenue, while continuing cash burn implies future debt or equity raises that could be dilutive and may be difficult to secure on acceptable terms. Additional downside comes from complex AAV and lentiviral manufacturing, regulatory uncertainty, reimbursement pressure in ultra-rare diseases, and a competitive landscape where safety, efficacy, and intellectual property risks could all limit commercialization.